Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Förderung der Gewichtsabnahme bei übergewichtigen Patienten mit peripherer arterieller Verschlusskrankheit (PAVK), um Mobilitätsverlust zu verhindern (PROVE)

22. September 2026 aktualisiert von: Mary McDermott, Northwestern University

PROmote-Gewichtsverlust bei adipösen Patienten mit peripherer arterieller Verschlusskrankheit (PAVK), um Mobilitätsverlust zu verhindern: Die PROVE-Studie

The PROVE Trial is a randomized clinical trial that will determine whether a weight loss intervention combined with walking exercise achieves greater improvement or less decline in six-minute walk distance at 12 month follow-up than walking exercise alone in people with PAD and BMI>25 kg/m2. The intervention uses a Group Mediated Cognitive Behavioral framework, connective mobile technology, remote monitoring by a coach, and a calorie restricted Dietary Approaches to Stop Hypertension (DASH)-derived Optimal Macronutrient Intake Trial for Heart Health (OMNIHeart) diet.

212 participants with PAD and BMI > 25 kg/m2 will be randomized to one of two groups: weight loss + exercise (WL+EX) vs. exercise alone (EX). Participants will be randomized at Northwestern, Tulane University, and University of Minnesota. Our primary outcome is change in six-minute walk distance at 12-month follow-up. Secondary outcomes are change in 6-minute walk distance at 6-month follow-up and change in exercise adherence, physical activity, patient-reported walking ability (measured by the Walking Impairment Questionnaire (WIQ) distance score), and mobility (measured by the Patient-Reported Outcomes Measurement Information System [PROMIS] mobility questionnaire) at 12-month follow-up. Tertiary outcomes are perceived exertional effort (measured by the Borg scale at the end of the 6-minute walk at 12-month follow-up), and diet quality. Exploratory outcomes consist of change in the short physical performance battery (SPPB), the WIQ stair climbing and walking speed scores, and calf muscle biopsy measures at 12-month follow-up. Study investigators will perform calf muscle biopsies in 50 participants to compare changes in mitochondrial biogenesis and activity, capillary density, and inflammation between WL+EX vs. EX.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

212

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Northwestern University
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70130
        • Tulane University
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Johns Hopkins University
    • Michigan
      • Detroit, Michigan, Vereinigte Staaten, 48202
        • Henry Ford Health
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55455
        • University of Minnesota
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • Ohio State University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion criteria are a) presence of PAD; b) BMI> 25 kg/m2; c) Age >= 18. The diagnosis of PAD will be based on the following. First, an ankle brachial index (ABI) value <= 0.90, which is a well-accepted standard for diagnosing PAD. People with a toe brachial index of <=0.70, performed at the study visit, will be eligible. Second, people with an ABI of >0.90 and <=1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included. Third, potential participants with an ABI > 0.90 who provide vascular laboratory evidence or angiographic evidence of PAD will be included. Prior vascular laboratory evidence consists of objective evidence of PAD including toe brachial index (TBI) < 0.70, Duplex measure showing 70% stenosis or greater, a post-exercise ABI drop in either leg of 20% or greater, or ABI values <= 0.90. Angiographic evidence of PAD consists of a stenosis of 70% or greater in a lower extremity artery. Fourth, people with a history of lower extremity revascularization who do not meet the criterion above and have an ABI > 0.90 with a 20% or higher drop in ABI after an exercise test will be eligible if they have symptomatic PAD. Symptomatic PAD will be defined as leg symptoms associated with exertion that resolved within 10 minutes of rest. The presence of symptomatic PAD will be determined based on the claudication questionnaire, the six-minute walk, or principal investigator interview/discussion with the potential participant. The post-exercise ABI drop will be measured by obtaining an ABI, having the participant exercise, and then immediately repeating the ABI. The exercise may consist of either the six-minute walk test or the heel-rise test. The heel-rise test consists of 50 heel rises at a rate of one per second. From the beginning of the trial until early 2023, we used the BMI inclusion criterion of > 28 kg/m2 because overweight and obesity are defined as a BMI of 25 to 29 kg/m2 and > 30 kg/m2, respectively, and because in our PAD cohorts, those with BMI > 28 kg/m2 have significantly greater functional impairment and faster functional decline than those with BMI of 20-28 kg/m2. In order to increase the rate of recruitment, on 1/19/2022, investigators reduced the BMI inclusion criterion to > 25 kg/ m2. People with BMI above 25 are overweight or obese and therefore are expected to benefit from the healthy lifestyle intervention.

Exclusion Criteria:

  1. Above or below knee amputation, critical limb ischemia, or wheelchair confinement.
  2. Walking is limited by a condition other than PAD.
  3. Failure to complete the study run-in, defined as not entering at least 800 Kcal of consumed calories per day for at least five days during the 14-day run-in*.
  4. Major surgery, coronary or leg revascularization in the past 3 months or anticipated in the next year.
  5. Experienced a heart attack or stroke in the past 3 months.
  6. Major medical illness including lung disease requiring oxygen or life-threatening illness, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent.
  7. Mini-Mental Status Examination (MMSE) score < 23, dementia and substance abuse. Potential participants with an MMSE score of less than 23 may be eligible if the principal investigator determines that their lower score is due to reasons other than poor cognition. Other potential reasons for lower scores include poor literacy or that English is not their first language.
  8. History of being treated for new onset or an acute episode of schizophrenia or psychosis in the past 6 months.
  9. Hospitalization for a psychiatric disorder in the past 6 months.
  10. BMI > 45 kg/m2
  11. History of a significant eating disorder that has been active within the past 5 years or any weight loss treatment in the past 6 months. Weight loss treatment includes weight watchers, any history of weight loss surgery, and using weight loss medications now or in the past six months.
  12. Weight gain or loss of more than 25 pounds in the past six months
  13. Potential participants unwilling/unable to use a smart phone and unwilling to attend weekly study sessions.
  14. Excessive alcohol use, defined as >14 drinks/week in men and > 10 alcoholic drinks/week in women.
  15. Current ulcer on bottom of foot
  16. Current participation in supervised treadmill exercise, participation in supervised treadmill exercise in the past three months, or planning to participate in supervised treadmill exercise in the next year
  17. Increase in angina or angina at rest. Potential participants may become eligible following an abnormal baseline treadmill stress test if they have evidence of an absence of coronary ischemia based on testing with their own physician.
  18. Non-English speaking
  19. Visual impairment that limits walking ability
  20. Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention
  21. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
  22. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Weight loss + exercise (WL+EX)

Weight loss + home based walking exercise (WL+EX)

Walking exercise combined with weight loss

Walking exercise

Aktiver Komparator: Exercise alone (EX)

Home based walking exercise (EX)

Walking exercise

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
12-month change in six-minute walk distance
Zeitfenster: Baseline to 12 months

Change in six-minute walk distance at 12-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.

Baseline to 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
12-month change in minutes of walking exercise/week
Zeitfenster: Baseline to 12 months

Change in minutes walked for exercise in a week will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone at 12-month follow-up.

Baseline to 12 months
12-month change in physical activity measured by accelerometer data
Zeitfenster: Baseline to 12 months

Change in physical activity at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. Change in physical activity will be compared using accelerometer data.

Baseline to 12 months
12-month change in Walking Impairment Questionnaire (WIQ) distance score
Zeitfenster: Baseline to 12 months

Change in Walking Impairment Questionnaire (WIQ) distance score at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. The WIQ distance score ranges from 0-100 with a higher score indicating a better outcome.

Baseline to 12 months
12-month change in Patient-Reported Outcomes Measurement Information System (PROMIS) mobility questionnaire
Zeitfenster: Baseline to 12 months

Change in Patient-Reported Outcomes Measurement Information System (PROMIS) mobility questionnaire score at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. A higher score is better. There is no set minimum and maximum values for the PROMIS questionnaire. However, a higher PROMIS score indicates a better outcome.

Baseline to 12 months
6-month change in 6-minute walk distance
Zeitfenster: Baseline to 6 months

Change in six-minute walk distance at 6-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.

Baseline to 6 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
12-month change in perceived exertional effort at the end of the six-minute walk test
Zeitfenster: Baseline to 12 months

Change in perceived exertional effort at the end of the six-minute walk test at 12-month follow-up will be compared between individuals randomized to the weight loss + exercise vs. those randomized to exercise alone. Perceived exertional effort will be measured using the Borg scale. The Borg scale is a 15-point scale ranging from six to 20. A higher score indicates greater perceived exertion.

Baseline to 12 months
12-month change in diet quality measured by change in Healthy Eating Index
Zeitfenster: Baseline to 12 months

Change in diet quality measured by change in Healthy Eating Index (HEI) will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. Change in diet quality will be measured at 12-month follow-up. The maximum HEI score is 100 points. A higher total HEI score indicates a diet that aligns better with dietary recommendations.

Baseline to 12 months
Change in the short physical performance (SPPB) battery questionnaire at 12-month follow-up
Zeitfenster: Baseline to 12 months

Change in the short physical performance (SPPB) battery questionnaire will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. The SPPB questionnaire ranges from 0 to 12 (12 = best).

Baseline to 12 months
Change in the WIQ walking speed score at 12-month follow-up
Zeitfenster: Baseline to 12 months

Change in the WIQ walking speed score at 12-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. The WIQ walking speed score ranges from 0-100. A higher score is better.

Baseline to 12 months
12-month change in calf muscle biopsy measured COX enzyme activity
Zeitfenster: Baseline to 12 months

In a subset of 50 participants, study investigators will compare improvement in calf muscle biopsy measures of mitochondrial activity (COX enzyme activity) between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.

Baseline to 12 months
12-month change in the calf muscle biopsy measure mitochondrial biogenesis (PGC-1α)
Zeitfenster: Baseline to 12 months

In a subset of 50 participants, study investigators will compare the calf muscle biopsy measures of mitochondrial biogenesis (PGC-1α) between individuals randomized to weight loss + exercise vs. those randomized to exercise alone.

Baseline to 12 months
Change in the WIQ stair climbing questionnaire score at 12-month follow-up
Zeitfenster: Baseline to 12 months

Change in the WIQ stair climbing questionnaire score at 12-month follow-up will be compared between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. The WIQ stair climbing score ranges from 0-100. A higher score is better.

Baseline to 12 months
12-month change in capillary density (capillaries per muscle fiber)
Zeitfenster: Baseline to 12 months

In a subset of 50 participants, study investigators will compare calf muscle biopsy measures of capillary density (capillaries per muscle fiber) between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. Change in capillary density will be measured at 12-month follow-up.

Baseline to 12 months
12-month change in calf muscle inflammation (IL-6, TNF-α, and IL1β)
Zeitfenster: Baseline to 12 months

In a subset of 50 participants, study investigators will compare calf muscle biopsy measures of calf muscle inflammation (IL-6, TNF-α, and IL1β) between individuals randomized to weight loss + exercise vs. those randomized to exercise alone. Change in calf muscle inflammation will be measured at 12-month follow-up.

Baseline to 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Mary M McDermott, MD, Northwestern University
  • Hauptermittler: Walter Ambrosius, PhD, Wake Forest University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. März 2020

Primärer Abschluss (Geschätzt)

30. Juni 2027

Studienabschluss (Geschätzt)

1. August 2027

Studienanmeldedaten

Zuerst eingereicht

8. Dezember 2019

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Januar 2020

Zuerst gepostet (Tatsächlich)

14. Januar 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren